UBC Study Finds Common Lactation Drug May Drastically Reduce Breast Cancer Risk

A medication traditionally prescribed to suppress milk production after childbirth could drastically lower a mother’s risk of developing breast cancer, according to new research co-led by the University of British Columbia.

The international study, published in Cancer Discovery, examined health data from over 150,000 women in Europe. Findings revealed that mothers administered cabergoline were nearly 70 per cent less likely to develop breast cancer in subsequent years.

Complementary lab testing on high-risk genetic models similarly demonstrated a 50 per cent decrease in tumor development following a single dose.

Researchers explain that after weaning, breast tissue undergoes a natural biological reset. When this process is incomplete, lingering cells can turn cancerous. Cabergoline appears to assist the body in fully clearing away these vulnerable cells, shrinking ductal tissue, and strengthening immune defense mechanisms without affecting a mother's chosen breastfeeding schedule.

With one in eight Canadian women facing a breast cancer diagnosis in their lifetime, scientists are preparing multinational clinical trials focusing on high-risk genetic carriers. Because cabergoline already holds Health Canada approval, successful trials could quickly offer women a gentler preventative alternative to surgery or heavy hormone treatments.